Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

Cited by (1,002)

Items 601–700 of 1,002

1. Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition
   Sarah Brem Sunshine, Susan Marie Dallabrida, Ellen M. Durand, Nesreen S. Ismail, Lauren F. Bazinet, Amy E. Birsner, Regina Lee Sohn, Sadakatsu Ikeda, William T. Pu, Matthew H. Kulke et al. · 2012 · Proceedings of the National Academy of Sciences
2. Endostar Suppresses Invasion Through Downregulating the Expression of Matrix Metalloproteinase-2/9 in MDA-MB-435 Human Breast Cancer Cells
   Na Lu, Yun Ling, Ying Gao, Yan Chen, Rong Mu, Qi Qi, Wei Liu, Haiwei Zhang, Hong-Yan Gu, Sen Wang et al. · 2008 · Experimental Biology and Medicine
3. Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo
   Jing Lin, Xiaojun Yan, Haimin Chen · 2006 · Cancer Chemotherapy and Pharmacology
4. Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice
   Qinglian Wen, Maobin Meng, Bo Yeun Yang, Ling‐Li Tu, Jia Li, Lin Zhou, Yong Xu, You Lü · 2009 · Cancer Science
5. Matrix metalloproteinases in tumour invasion and metastasis
   Stephanie Curran, Graeme I. Murray · 1999 · The Journal of Pathology
6. Influence of endostatin on embryonic vasculo‐ and angiogenesis
   Annette Schmidt, Daniela Wenzel, Isabell Ferring, Shohreh Kazemi, Takako Sasaki, Jürgen Hescheler, Rupert Timpl, Klaus Addicks, Bernd K. Fleischmann, Wilhelm Bloch · 2004 · Developmental Dynamics
7. Approaches for chronic disease prevention based on current understanding of underlying mechanisms
   John H. Weisburger · 2000 · American Journal of Clinical Nutrition
8. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF
   Seock‐Ah Im, J-S Kim, Candelaria Gomez‐Manzano, Juan Fueyo-Margareto, T. J. Liu, M. S. Cho, C-M Seong, S N Lee, Y K Hong, W. K. Alfred Yung · 2001 · British Journal of Cancer
9. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody
   Zhenping Zhu, Dan Lu, Helen Kotanides, Angel Santiago, Xenia Jimenez, Tim Simcox, Daniel J. Hicklin, Peter Böhlen, Larry Witte · 1999 · Cancer Letters
10. New strategies in anti‐vascular cancer therapy
    Bloemendal, Logtenberg, Voest · 1999 · European Journal of Clinical Investigation
11. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.
    Keiji Inoue, Masakazu Chikazawa, Satoshi Fukata, Chiaki Yoshikawa, Taro Shuin · 2002 · PubMed
12. Hormone‐activated nuclear receptors inhibit the stimulation of the JNK and ERK signalling pathways in endothelial cells
    Marı́a Victoria González, José Manuel González‐Sancho, Carmé Caelles, Alberto Múñoz, Benilde Jiménez · 1999 · FEBS Letters
13. Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy
    Dong Wook Kim, Jessica Huamani, Allie Fu, Dennis E. Hallahan · 2005 · International Journal of Radiation Oncology*Biology*Physics
14. Novel Anticancer Agents in Clinical Development
    Alex A. Adjei, Eric Keith Rowinsky · 2003 · Cancer Biology & Therapy
15. The promise of anti-angiogenic cancer therapy
    Martin Klaus Oehler, Roy Bicknell · 2000 · British Journal of Cancer
16. Long–Term Expression of Angiostatin Suppresses Metastatic Liver Cancer in Mice
    Ruian Xu, Xueying Sun, Lai Yin Tse, Hua Li, Pui-Chung Chan, Sue Xu, Weidong Xiao, Hsiang‐Fu Kung, Geoffrey Wayne Krissansen, Sheung-Tat Fan · 2003 · Hepatology
17. Targeting Tumor Angiogenesis with Gene Therapy
    Qingrong Chen, Lei Justan Zhang, Warren J. Gasper, Archibald James Mixson · 2001 · Molecular Genetics and Metabolism
18. Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin
    Judah Folkman · 2006 · Science s STKE
19. NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity.
    Rabih M. Salloum, Nora T. Jaskowiak, Helena J. Mauceri, Saraswathy Seetharam, M A Beckett, Ann Koons, Danielle M. Hari, Vinay Kumar Gupta, Corinne Reimer, Raghu Kalluri et al. · 2000 · PubMed
20. A family of glycolipids from Toxoplasma gondii. Identification of candidate glycolipid precursor(s) for Toxoplasma gondii glycosylphosphatidylinositol membrane anchors.
    Stanislas Tomavo, Jean‐François Dubremetz, Ralph Τ. Schwarz · 1992 · Journal of Biological Chemistry
21. Angiogenesis inhibitors in clinical development for lung cancer
    Roy S. Herbst, Manuel M. Hidalgo, A. Scott Pierson, Scott N. Holden, Michael Bergen, S. Gail Eckhardt · 2002 · Seminars in Oncology
22. The use of GEM models for experimental cancer therapeutics
    Aarthi Gopinathan, David Arthur Tuveson · 2008 · Disease Models & Mechanisms
23. Nanoparticles modified with vasculature-homing peptides for targeted cancer therapy and angiogenesis imaging
    Elham Seyyednia, Fatemeh Oroojalian, Behzad Baradaran, Javid Shahbazi Mojarrad, Ahad Mokhtarzadeh, Hadi Valizadeh · 2021 · Journal of Controlled Release
24. Endostatin: Current concepts about its biological role and mechanisms of action
    А В Дигтярь, Natalia V. Pozdniakova, Nataliya B. Feldman, Sergey V. Lutsenko, E. S. Severin · 2007 · Biochemistry (Moscow)
25. Limitations of therapies exposed
    Oriol Casanovas · 2012 · Nature
26. Is copper chelation an effective anti-angiogenic strategy for cancer treatment?
    Vasilis Antoniades, Antonia Sioga, E.M. Dietrich, Soultana Meditskou, L. Ekonomou, Kostas Antoniades · 2013 · Medical Hypotheses
27. Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice
    J A Lyons, Brian J. Sheahan, Sareen Elizabeth Galbraith, Reena Mehra, Gerald J. Atkins, Marina N. Fleeton · 2006 · Gene Therapy
28. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein
    Hyun-Mi Cho, Joseph D. Rosenblatt, Young‐Sook Kang, M. Luisa Iruela‐Arispe, Sherie Leaver Morrison, Manuel L. Penichet, Young‐Guen Kwon, Tae‐Woong Kim, Keith A. Webster, Hovav Nechushtan et al. · 2005 · Molecular Cancer Therapeutics
29. Long‐term results of a randomized, double‐blind, and placebo‐controlled phase III trial: Endostar (rh‐endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non‐small cell lung cancer
    Yan Kui Sun, Jin Wan Wang, Yu Liu, Qi Yu, Yi Ping Zhang, Kai Li, Li Xu, Su Xia Luo, Feng Zhan Qin, Zheng Tang Chen et al. · 2013 · Thoracic Cancer
30. NF-κB activation in endothelial cells is critical for the activity of angiostatic agents
    Sébastien P. Tabruyn, Sylvie Mémet, Patrick Avé, Catherine Verhaeghe, Kevin H. Mayo, Ingrid Struman, JOSEPH A. MARTIAL, Arjan W. Griffioen · 2009 · Molecular Cancer Therapeutics
31. Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer.
    M.G. Sacco, M. Caniatti, Enrica Mira Catò, A Frattini, G Chiesa, Roberta Ceruti, Fulvio Adorni, Luigi Zecca, Eugenio Scanziani, Paolo Vezzoni · 2000 · PubMed
32. Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin
    Roy S. Herbst, Anh Tuyet Lee, Hai Thanh Tran, James L. Abbruzzese · 2001 · Current Oncology Reports
33. Angiogenesis factors in gliomas: a new key to tumour therapy?
    Rolf Mentlein, Janka Held‐Feindt · 2003 · Die Naturwissenschaften
34. Antiangiogenic strategies in neuroblastoma
    Doménico Ribatti, Mirco Ponzoni · 2004 · Cancer Treatment Reviews
35. Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
    Lloyd R. Kèlland · 2005 · Current Cancer Therapy Reviews
36. Systemic Delivery of Antiangiogenic Adenovirus AdmATF Induces Liver Resistance to Metastasis and Prolongs Survival of Mice
    Hong Li, Frank Griscelli, Frederique Lindenmeyer, Paule Opolon, Lin-Qian Sun, Elisabeth Connault, J. Soria, Claudine Soria, Michel Perricaudet, Patrice Yeh · 1999 · Human Gene Therapy
37. Angiogenesis and antiangiogenic approaches to sarcomas
    John Victor Heymach · 2001 · Current Opinion in Oncology
38. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice
    Satoshi Itasaka, Ritsuko K. Komaki, Roy S. Herbst, Keiko Shibuya, Tomoaki Shintani, Nancy R. Hunter, Amir Onn, Corazon D. Bucana, Luka Milas, K. Kian Ang et al. · 2007 · International Journal of Radiation Oncology*Biology*Physics
39. Spatial Evolutionary Games of Interaction among Generic Cancer Cells
    Lars A. Bach, David J. T. Sumpter, Jan Alsner, Volker Loeschcke · 2003 · Computational and Mathematical Methods in Medicine
40. Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases
    Ralph Mazitschek, Athanassios Giannis · 2004 · Current Opinion in Chemical Biology
41. Inhibition of Vascularization in Tumor Growth
    Marco Scalerandi, Barbara Capogrosso-Sansone · 2002 · Physical Review Letters
42. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma
    Francesco Bertolini, Lisa Fusetti, Cristina Rabascio, Saverio Cinieri, Giovanni Martinelli, Giancarlo Pruneri · 2000 · Leukemia
43. Prostaglandins, but not tumor-derived IL-10, shut down concomitant tumor-specific CTL responses during murine plasmacytoma progression
    Christiane Specht, Stephanie Bexten, Eckehart Kölsch, Hans‐Gerd Pauels · 2001 · International Journal of Cancer
44. Human Prothrombin Fragment 1 and 2 Inhibit bFGF-Induced BCE Cell Growth
    Tai Youn Rhim, Chan-Soo Park, Eun‐Kyung Kim, Soung Soo Kim · 1998 · Biochemical and Biophysical Research Communications
45. Early Genetic Mechanisms Underlying the Inhibitory Effects of Endostatin and Fumagillin on Human Endothelial Cells
    Endothelial Cells, Chiara M. Mazzanti, Dominique Lorang, Dominique Lorang, David Roberts, Generoso Bevilacqua, Generoso Bevilacqua · 2004 · Genome Research
46. Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy
    Arkadiusz Zbigniew Dudek, Vidya Bodempudi, B W Welsh, Piotr Jasiński, Robert J. Griffin, Liming Chang Milbauer, Robert P. Hebbel · 2007 · British Journal of Cancer
47. Contributions of Zn(II)‐binding to the structural stability of endostatin
    Qing Han, Yan Fu, Hao Zhou, Yingbo He, Yongzhang Luo · 2007 · FEBS Letters
48. Angiogenesis and anti-angiogenesis: Perspectives for the treatment of solid tumors
    Victor W.M. van Hinsbergh, Annemie Collen, Pieter Koolwijk · 1999 · Annals of Oncology
49. Diurnal variations in angiostatin in human tear fluid: A possible role in prevention of corneal neovascularization
    Robert A. Sack, Ann R. Beaton, Sonal Sathe · 1999 · Current Eye Research
50. Control of vascular endothelial growth factor angiogenic activity by the extracellular matrix
    Ortéga, Nathalie, L'Faqihi, Fatima‐Ezzahra, Plouët, Jean · 1998 · Biology of the Cell
51. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU‐68)
    静生 町田, Yasushi Saga, Yuji Takei, Izumi Mizuno, Takeshi Takayama, Takahiro Kohno, Ryo Konno, Michitaka Ohwada, Mitsuaki Suzuki · 2004 · International Journal of Cancer
52. DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability
    Mehmet Ali Sahin, Emel Şahın, Saadet Gümüşlü, Abdullah Erdoğan, Meral Gültekin · 2010 · Cancer and Metastasis Reviews
53. CCI-779 plus Cisplatin Is Highly Effective against Human Melanoma in a SCID Mouse Xenotranplantation Model
    Christiane Thallinger, Wolfgang Poeppl, Barbara Pratscher, Marius Mayerhöfer, Peter Valent, Gerhard Tappeiner, Christian Joukhadar · 2007 · Pharmacology
54. Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia
    Nils Idar Glenjen, Knut Anders Mosevoll, Øystein Bruserud · 2002 · International Journal of Cancer
55. Trichostatin A—histone deacetylase inhibitor with clinical therapeutic potential—is also a selective and potent inhibitor of gelatinase A expression
    Menachem Ailenberg, Mel Silverman · 2002 · Biochemical and Biophysical Research Communications
56. A phase 1 trial of 2 dose schedules of ABT‐510, an antiangiogenic, thrombospondin‐1‐mimetic peptide, in patients with advanced cancer
    Michael S. Gordon, David S. Mendelson, Robert Carr, Raymond A. Knight, Rod A. Humerickhouse, Maria Iannone, Alison Stopeck · 2008 · Cancer
57. Rocking the foundations of solid tumor growth by attacking the tumor's blood supply
    Grietje Molema, Arjan W. Griffioen · 1998 · Immunology Today
58. Mechanisms of tumor cell invasion and angiogenesis in the central nervous system
    Rolf Bjerkvig · 2003 · Frontiers in bioscience
59. Resistance in the anti-angiogenic era: nay-saying or a word of caution?
    Christopher J. Sweeney, Kathy D. Miller, George W. Sledge · 2003 · Trends in Molecular Medicine
60. Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system.
    Arie Reijerkerk, Laurent O. Mosnier, Onno Kranenburg, Bonno N. Bouma, Peter Carmeliet, Tom A. Drixler, Joost C.M. Meijers, Emile E. Voest, Martijn F.B.G. Gebbink · 2003 · PubMed
61. The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice
    Jack L. Arbiser, Dipak Panigrathy, Nancy Klauber, Maria Ann Rupnick, Evelyn Flynnb, Taturo Udagawa, Robert J. D’Amato · 1999 · Journal of the American Academy of Dermatology
62. TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo
    Kristina Petrovic, Joseph A. Robinson, Katharine Whitworth, Elizabeth Jinks, Abeer M. Shaaban, Steven P. Lee · 2019 · PLoS ONE
63. Lack of Collagen XVIII/Endostatin Exacerbates Immune-Mediated Glomerulonephritis
    Yuki Hamano, Takashi Okude, Ryota Shirai, Ikumi Sato, Ryota Kimura, Makoto Ogawa, Yoshihiko Ueda, Osamu Yokosuka, Raghu Kalluri, Shiro Ueda · 2010 · Journal of the American Society of Nephrology
64. Lack of Antitumor Activity of Recombinant Endostatin in a Human Neuroblastoma Xenograft Model
    Emmanuel Jouanneau, Laurent Alberti, Mimoun Nejjari, Isabelle Treilleux, Isabelle Vilgrain, Adeline Duc, Valérie Combaret, M Favrot, Philippe Leboulch, Thomas Bachelot · 2001 · Journal of Neuro-Oncology
65. A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models
    Stuart L. Emanuel, Robert H. Gruninger, Angel R. Fuentes‐Pesquera, Peter J. Connolly, Jennifer A. Seamon, Susan J. Hazel, Rose M. Tominovich, Beth A. Hollister, Cheryl Napier, Michael R. D’Andrea et al. · 2004 · Molecular Pharmacology
66. AngiostatinTM and EndostatinTM:endothelial cell-specific endogenous inhibitorsof angiogenesis and tumor growth
    B. Kim Lee Sim · 1998 · Angiogenesis
67. Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model
    Giselle V. Ripoll, Juan Garona, Marina Pífano, Hernán G. Fariña, Daniel Eduardo Gomez, Daniel F. Alonso · 2013 · Breast Cancer Research and Treatment
68. A Review of Angiogenesis and Anti-Angiogenic Therapy in Hematologic Malignancies
    S. Vincent Rajkumar, Ruben A. Mesa, Ayalew Tefferi · 2002 · Stem Cells and Development
69. Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
    María Esperanza Ruiz, Melisa E. Gantner, Alan Talevi · 2013 · Recent Patents on Anti-Cancer Drug Discovery
70. High-Dose Atorvastatin Improves Hypercholesterolemic Coronary Endothelial Dysfunction Without Improving the Angiogenic Response
    Munir Boodhwani, Yasunari Nakai, Pierre Voisine, Jun Feng, Jian Li, Shigetoshi Mieno, Basel Ramlawi, Cesario F. Bianchi, Roger J. Laham, Frank William Sellke · 2006 · Circulation
71. Gene therapy for cancer
    Jesús Gómez-Navarro, David T. Curiel, Joanne T. Douglas · 1999 · European Journal of Cancer
72. Treatment of Experimental Brain Tumors with Trombospondin-1 Derived Peptides: an In Vivo Imaging Study
    Alexei A. Bogdanov Jr, E Marecos, Hao‐Tsai Cheng, L. Chandrasekaran, Henry C. Krutzsch, David D. Roberts, Ralph Weissleder · 1999 · Neoplasia
73. Are angiostatin and endostatin cures for cancer?
    Adrian Llewellyn Harris · 1998 · The Lancet
74. Combination of low‐dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities
    Guang‐Hong Tan, Ling Tian, Yu‐quan Wei, Xia Zhao, Jiong Li, Yang Wu, Yanjun Wen, Tao Yi, Zhenyu Ding, Bin Kan et al. · 2004 · International Journal of Cancer
75. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways
    Seung Woo Chung, Sang Mun Bae, Myungjin Lee, Taslim Ahmed Al-Hilal, Chang Kyung Lee, Jeong Kon Kim, In‐San Kim, Sang Yoon Kim, Youngro Byun · 2014 · Biomaterials
76. A Journey in Structure-Based Drug Discovery: From Designed Peptides to Protein Surface Topomimetics as Antibiotic and Antiangiogenic Agents
    Ruud P.M. Dings, Kevin H. Mayo · 2007 · Accounts of Chemical Research
77. Self-Assembling Peptides: Potential Role in Tumor Targeting
    Parisa Sadatmousavi, Madjid Soltani, Reyhaneh Nazarian, Mousa Jafari, P. Chen · 2011 · Current Pharmaceutical Biotechnology
78. Collateral Damage Intended—Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy
    Ana C. Martins Cavaco, Maryam Rezaei, Stephan Niland, Johannes Andreas Eble · 2017 · International Journal of Molecular Sciences
79. Vaccines targeting tumour angiogenesis—a novel strategy for cancer immunotherapy
    Yurai Okaji, Nelson Hirokazu Tsuno, Seiichi Saito, Satomi Yoneyama, Minoru Tanaka, Hirokazu Nagawa, Kei Takahashi · 2006 · European Journal of Surgical Oncology
80. Inflammatory synovial fluid microenvironment drives primary human chondrocytes to actively take part in inflammatory joint diseases
    Eric Röhner, Georg Matziolis, Carsten Perka, Bernd Füchtmeier, Timo Gaber, Gerd Rüdiger Burmester, Frank Buttgereit, Paula Hoff · 2011 · Immunologic Research
81. Æ-941 (Neovastat®): a novel multifunctional antiangiogenic compound
    Denis Gingras, Gerald Batist, Richard Béliveau · 2001 · Expert Review of Anticancer Therapy
82. Antiangiogenic strategies, compounds, and early clinical results in breast cancer
    Alessandro Morabito, Roberta Sarmiento, Paola Bonginelli, Giampietro Gasparini · 2004 · Critical Reviews in Oncology/Hematology
83. Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo
    Xiaomei Jin, Rob Bookstein, Ken N. Wills, Jenny B. Avanzini, Van Tsai, Drake LaFace, Gaby Terracina, Bin Shi, Loretta L. Nielsen · 2001 · Cancer Gene Therapy
84. Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans
    Renata C.M. Reis, Detlef Schuppan, Aline C. Barreto, Michael W Bauer, Jens Peter Bork, Gerda Hassler, Tatiana Coelho‐Sampaio · 2005 · Biochemical and Biophysical Research Communications
85. Expression of endothelial cell-associated molecules in AML cells
    Masaya Watarai, Hiroto Miwa, Masato Shikami, Kazutaka Sugamura, Motohiro Wakabayashi, Atsushi Satoh, Kayoko Tsuboi, Akira Imamura, H Mihara, Yoshiro Katoh et al. · 2002 · Leukemia
86. Perindopril: possible use in cancer therapy
    Hitoshi Yoshiji, Shigeki Kuriyama, Hiroshi Fukui · 2002 · Anti-Cancer Drugs
87. Endothelial Cell-Specific Transcriptional Targeting from a Hybrid Long Terminal Repeat Retrovirus Vector Containing Human Prepro-Endothelin-1 Promoter Sequences
    Ute Jäger, Yuan Zhao, Colin D. Porter · 1999 · Journal of Virology
88. Direct effects of fascaplysin on human umbilical vein endothelial cells attributing the anti-angiogenesis activity
    Y.L. Zheng, X. L. LU, Jing‐Jer Lin, H.M. Chen, Xiao Jun Yan, F. Wang, W.F. Xu · 2009 · Biomedicine & Pharmacotherapy
89. The dynamics of tumour–vasculature interaction suggests low‐dose, time‐dense anti‐angiogenic schedulings
    Alberto d’Onofrio, Alberto Gandolfi, Andrea Rocca · 2009 · Cell Proliferation
90. Effects of Tetrahydrocurcumin on Hypoxia-Inducible Factor-1 α and Vascular Endothelial Growth Factor Expression in Cervical Cancer Cell-Induced Angiogenesis in Nude Mice
    Bhornprom Yoysungnoen, Parvapan Bhattarakosol, Suthiluk Patumraj, Chatchawan Changtam · 2015 · BioMed Research International
91. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma
    Siddharth J. Modi, Vithal M. Kulkarni · 2020 · European Journal of Medicinal Chemistry
92. Design, Synthesis, and Anticancer Properties of Novel Benzophenone‐Conjugated Coumarin Analogs
    V. Lakshmi Ranganatha, Farhan Zameer, S. Meghashri, Nanjappagowda Dharmappa Rekha, Virupaksha Girish, Handuvinahalli Devanna Gurupadaswamy, Shaukath Ara Khanum · 2013 · Archiv der Pharmazie
93. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: Differences in growth rate and therapeutic response between tumors growing at different sites
    Masanori Tsujie, Shima Uneda, Hilda Tsai, Ben K. Seon · 2006 · International Journal of Oncology
94. Cancer Gene Therapy
    Masato Yamamoto, David T. Curiel · 2005 · Technology in Cancer Research & Treatment
95. Suppression of Colorectal Cancer Liver Metastasis and Extension of Survival by Expression of Apolipoprotein(a) Kringles
    Hyun-Kyung Yu, Jang-Seong Kim, Ho-Jeong Lee, Jin-Hyung Ahn, Suk-Keun Lee, Soon Won Hong, Yeup Yoon · 2004 · Cancer Research
96. Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors
    H-L Li, S Li, J-Y Shao, X-B Lin, Yongtong Cao, W-Q Jiang, R-Y Liu, Peng Zhao, X-F Zhu, M-S Zeng et al. · 2007 · Gene Therapy
97. Cholecalciferol-PEG Conjugate Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer
    Shallu Kutlehria, Gautam Behl, Ketan R. Patel, Ravi Doddapaneni, Imran Vhora, Nusrat Chowdhury, Arvind Bagde, Mandip S. Singh · 2017 · AAPS PharmSciTech
98. Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’
    Romano Demicheli, Rosalba Miceli, Cristina Brambilla, L. Ferrari, Angela Moliterni, Milvia Zambetti, Pinuccia Valagussa, Gianni Bonadonna · 1999 · Breast Cancer Research and Treatment
99. The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era
    Kathy D. Miller, Christopher J. Sweeney, George W. Sledge · 2002 · Annals of Oncology
100. Angiostatic Treatment of Neuroblastoma
     Erik Wassberg · 1999 · Upsala Journal of Medical Sciences